Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma

NCT01845038 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma

Interventions

DRUG: OTX-TPa ~4µg/day over 2 mos. with natural tears drops
DRUG: OTX-TPb ~3µg/day over 3 months with natural tears drops
DRUG: Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug

Sponsor

Ocular Therapeutix, Inc.